Correlation of CA 19-9 with HbA1c in prediabetic and diabetic groups

Pratheeksha Pratheeksha,Vinod Chandran,Gayathri M Rao ,D Narayana Rao

doi:10.51248/.v41i4.909

Pratheeksha Pratheeksha, Vinod Chandran + Show 2 more

Open Access

https://doi.org/10.51248/.v41i4.909

Copy DOI

Abstract

Introduction and Aim: Carbohydrate antigen19-9 (CA 19-9) is a marker of pancreatic cancer. In diabetics, pancreatic beta cell dysfunction can lead to elevated serum CA19-9 level. This study was designed for estimation of CA19-9 in diabetes and its correlation with glucose levels and glycosylated hemoglobin. Materials and Methods: The includes diabetic, pre diabetic with no history of malignancies and healthy normal subjects (n=50 each). Ca19-9 was estimated using ELISA, HbA1c by D10-Biorad variant turbo and the Lipid profile in Roche COBAs 6000 auto analyzer. Statistical analysis was done by Statistical Package for Social Sciences software version17 (SPSS 17). P <0.05 was considered significant. Results: Serum CA19-9 level was high in diabetics compared to normal, (p=0.38) however it was decreased in pre diabetic group (P=0.06). There was significant difference in comparison of CA19-9 levels between pre diabetic and diabetics(p=0.001). A significant increase in triglycerides was observed both in diabetics (p<0.01) and pre-diabetics(p=0.04). There was a significant positive correlation of CA19-9 with TC/HDL (p=0.022) and non-HDL(p) in control group. Conclusion: CA19-9 levels can be influenced by glycemic status, hence assessment of pancreatic cancer in diabetic patients must be interpreted carefully in consideration with CA19-9 levels. CA19-9 level was decreased in prediabetics when compared to normal and diabetics. This is a novel finding, the cause for which must ascertained, and this will open further avenues for research.

Highlights

Introduction and AimCarbohydrate antigen19-9 (CA 19-9) is a marker of pancreatic cancer
CA19-9 levels can be influenced by glycemic status, assessment of pancreatic cancer in diabetic patients must be interpreted carefully in consideration with CA19-9 levels
Subjects were divided into 3 groups based on the glucose values, 50 cases of prediabetic, 50 cases of diabetic and 50 of normal control, samples obtained in clinical biochemistry section of KMC Laboratory Services (KMCLS), situated at KMC Hospital Ambedkar Circle (KMCHAC), Mangalore, Karnataka, India

Summary

Introduction

Introduction and AimCarbohydrate antigen (CA 19-9) is a marker of pancreatic cancer. Diabetes mellitus is a cluster of metabolic syndromes in which the capability to produce insulin is reduced and results in hyperglycemia, which leads to the signs such as frequent urination, increased thirstiness, and hunger and further to several secondary consequences. It can be either severe complications such as diabetic acidosis, non-ketotic hyperosmolar coma or serious long-term complications such as cardiac disease, stroke, chronic kidney disease, foot ulcer and damage to the eyes. Diabetic mellitus can be a risk factor for pancreatic, hepatic duct, breast, ascending tract, and rectal cancer [1]

Methods

Results

Discussion

Conclusion